- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04677335
Combination of AB-LIFE Probiotic Plus Monacolin K to Reduce Blood Cholesterol
January 19, 2021 updated by: AB Biotics, SA
Effect of a Nutritional Supplement (AB-LIFE Plus Monacolin K) to Reduce Total and LDL Cholesterol Levels
This randomized study evaluates the effectiveness of a nutraceutical combining billion colony forming units (cfu) of three L. plantarum strains (CECT7527, CECT7528 and CECT7529) and 10 mg of monacolin K in reducing blood cholesterol.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Cardiovascular diseases (CVDs) are the number 1 cause of death globally, and retention of low-density lipoprotein cholesterol (LDL-C) and similar cholesterol-rich lipoproteins containing apolipoprotein B (ApoB) within the arterial wall is a key initiating event in CVDs.
Statins are the mainstay of pharmacological cholesterol-reduction therapy.
However, a significant proportion of patients report some degree of statin intolerance, which typically fade away when the statin is switched, discontinued or the dosage reduced.
A growing attention has been devoted to the correction of increased LDL-C levels through the use of dietary supplements, either because some patients have milder forms of hypercholesterolemia or as an alternative to statins in patients who may have experienced or are worried of side effects.
Nutraceutical combinations are increasingly used in clinical practice.
In this pilot randomized study, we sought to evaluate of the effect on LDL-C and other blood lipid parameters of a nutraceutical combining Red Yeast Rice extract (also known by its scientific name Monascus purpureus) containing 10 mg of monacolin K, plus 1 billion colony forming units (cfu) of the AB-LIFE probiotic formula.
The later is composed of three L. plantarum strains, namely CECT7527 (also known as KABP011™), CECT7528 (also known as KABP012™) and CECT7529 (also known as KABP013™).
Study Type
Interventional
Enrollment (Actual)
40
Phase
- Not Applicable
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 68 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Total cholesterol (TC) ≥200 mg/dL and statin-naïve or having recently stopped statin treatment because of statin intolerance.
Exclusion Criteria:
- History of cardiovascular events or alcohol abuse, presence of diabetes, chronic advanced kidney disease, thyroid disorders, hepatic disorders, familial hypercholesterolemia or immunosuppression
- Body mass index (BMI) ≤ 18.5 or ≥40 Kg/m2
- Use of antibiotics within 4 weeks of study initiation, current use of other probiotics, lipid-lowering medications, corticoids, beta-blockers or calcium channel blockers, thiazide diuretics, estrogen replacement therapy
- Pregnant or lactating women
- Patients with other severe disease that could interfere with the results of the study.
- Patients not agreeing to maintain their usual physical activity throughout the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Nutraceutical
Nutraceutical capsules taken once daily for 12 weeks
|
Red yeast rice extract (also known by its scientific name, Monascus purpureus) certified to contain 10 mg of monacolin K, plus 1 billion total cfu of AB-LIFE probiotic formula, which is composed of 3 Lactoplantibacillus plantarum (formerly known as Lactobacillus plantarum) strains: CECT7527 (also known as KABP011™), CECT7528 (also known as KABP012™) and CECT7529 (also known as KABP013™), all in a maltodextrin carrier.
Capsules are of vegetable origin (hydroxypropylmethyl cellulose).
|
Placebo Comparator: Control
Placebo capsules taken once daily for 12 weeks
|
Placebo capsules containing maltodextrin carrier only.
Capsules are of vegetable origin (hydroxypropylmethyl cellulose).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in low density lipoprotein cholesterol (LDL-C)
Time Frame: 0, 6 and 12 weeks
|
Fasting serum levels of low density lipoprotein cholesterol (LDL-C), assessed by repeated measures analysis at three timepoints (baseline, mid of intervention and end of intervention).
|
0, 6 and 12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in total cholesterol (TC)
Time Frame: 0, 6 and 12 weeks
|
Fasting serum levels of total cholesterol (TC), assessed by repeated measures analysis at three timepoints (baseline, mid of intervention and end of intervention).
|
0, 6 and 12 weeks
|
Change in high density lipoprotein cholesterol (HDL-C)
Time Frame: 0, 6 and 12 weeks
|
Fasting serum levels of high density lipoprotein cholesterol (HDL-C), assessed by repeated measures analysis at three timepoints (baseline, mid of intervention and end of intervention).
|
0, 6 and 12 weeks
|
Change in triglycerides (TG)
Time Frame: 0, 6 and 12 weeks
|
Fasting serum levels of triglycerides (TG), assessed by repeated measures analysis at three timepoints (baseline, mid of intervention and end of intervention).
|
0, 6 and 12 weeks
|
Change in Body Mass Index (BMI)
Time Frame: 0 and 12 weeks
|
Body Mass Index, calculated as body weight (in kilograms) divided by squared height (in meters), assessed by repeated measures analysis at two timepoints (baseline and end of intervention).
|
0 and 12 weeks
|
Change in body weight
Time Frame: 0 and 12 weeks
|
Body weight in kilograms, assessed by repeated measures analysis at two timepoints (baseline and end of intervention).
|
0 and 12 weeks
|
Change in percent body fat
Time Frame: 0 and 12 weeks
|
Percent of body fat (as determined with a MC780 Body Analyzer), assessed by repeated measures analysis at two timepoints (baseline and end of intervention).
|
0 and 12 weeks
|
Patient satisfaction with treatment
Time Frame: 12 weeks
|
Rated with a Likert-type scale ranging 0 (very dissatisfied) to 4 (very satisfied), assessed at the end of the intervention.
|
12 weeks
|
Treatment-emergent adverse effects
Time Frame: 12 weeks
|
Incidence of adverse effects (type and number) and relatedness to study product (using a 5 category system: certain, likely related, possibly related, conditionally related, unknown), as documented according to the Spanish Medicine and Medical Device Agency (AEMPS) pharmacovigilance system
|
12 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Rafael Guerrero Bonmatty, PhD, University of Extremadura (SPAIN)
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 1, 2014
Primary Completion (Actual)
April 15, 2016
Study Completion (Actual)
September 19, 2017
Study Registration Dates
First Submitted
November 27, 2020
First Submitted That Met QC Criteria
December 15, 2020
First Posted (Actual)
December 21, 2020
Study Record Updates
Last Update Posted (Actual)
January 22, 2021
Last Update Submitted That Met QC Criteria
January 19, 2021
Last Verified
January 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Metabolic Diseases
- Lipid Metabolism Disorders
- Hyperlipidemias
- Dyslipidemias
- Hypercholesterolemia
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antimetabolites
- Anticholesteremic Agents
- Hypolipidemic Agents
- Lipid Regulating Agents
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Lovastatin
Other Study ID Numbers
- PRIMACOL01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypercholesterolemia
-
National Medical Research Center for Therapy and...Moscow State University of Medicine and DentistryRecruitingMedication Adherence | Adherence, Medication | Treatment Adherence | Familial Hypercholesterolemia | Motivational Interviewing | Adherence, Patient | Treatment Adherence and Compliance | Patient Compliance | Adherence | Hypercholesterolemia, Familial | Patient Adherence | Hypercholesterolemia, Autosomal Dominant and other conditionsRussian Federation
-
Direct PlantesUnknownHYPERCHOLESTEROLEMIAFrance
-
Chong Kun Dang PharmaceuticalRecruitingPrimary HypercholesterolemiaKorea, Republic of
-
Addpharma Inc.CompletedPrimary HypercholesterolemiaKorea, Republic of
-
JW PharmaceuticalCompletedPrimary HypercholesterolemiaKorea, Republic of
-
Hanmi Pharmaceutical Company LimitedCompletedPrimary HypercholesterolemiaKorea, Republic of
-
Provident Clinical ResearchGlaxoSmithKlineUnknownPrimary HypercholesterolemiaUnited States
-
Organon and CoCompletedPrimary Hypercholesterolemia | Homozygous Familial Hypercholesterolemia
-
Boryung Pharmaceutical Co., LtdRecruitingPrimary HypercholesterolemiaKorea, Republic of
-
Ahn-Gook Pharmaceuticals Co.,LtdRecruitingPrimary HypercholesterolemiaKorea, Republic of
Clinical Trials on AB-LIFE with Monacolin K
-
Fluart Innovative Vaccine Ltd, HungaryCompletedInfluenza, Human | Novel 2009 Influenza H1N1Hungary
-
AB Biotics, SACompletedModerate HypercholesterolemiaFrance
-
Shanghai Eye Disease Prevention and Treatment CenterUnknown
-
HK inno.N CorporationCompletedHealthyKorea, Republic of
-
Istituto Clinico HumanitasUnknown
-
Long Neck Medical EnterprisesNational Institutes of Health (NIH)Unknown
-
Children's Mercy Hospital Kansas CityCompleted
-
Fluart Innovative Vaccine Ltd, HungaryCompleted
-
Fluart Innovative Vaccine Ltd, HungaryCompletedInfluenza ProphylaxisHungary
-
Assiut UniversityCompletedGlaucoma | Glaucoma, Angle-Closure | OphthalmopathyEgypt